References
- WHO. R & D blueprint list of blueprint priority diseases; 2018 1–3 [cited 2020 Jul 19]. Available from: http://origin.who.int/blueprint/priority-diseases/en/
- Waggoner JJ, Pinsky A. Zika virus: diagnostics for an emerging pandemic threat. J Clin Microbiol. 2016;54:860–867.
- Gutiérrez-Bugallo G, Piedra LA, Rodriguez M, et al. Vector-borne transmission and evolution of Zika virus. Nat Ecol Evol. 2019;3:561–569.
- Viveiros-Rosa SG, Regis EG, Santos WC. Vector competence of Culex mosquitoes (Diptera : culicidae) in Zika virus transmission: an integrative review. Pan Am J Public Health. 2020;1–9. DOI:10.26633/RPSP.2020.7
- Dick GWA, Kitchen SF, Haddow AJ. (I). Zika vírus (I). Isolations and serological specificity. Transactions of the royal society of literature. Notes Queries. 1952;46:509–20.
- Pan American Health Organization/World Health Organization. Zika suspected and confirmed cases reported by countries and territories in the Americas cumulative cases, 2015–2017. Washington, D.C.: PAHO/WHO; 2017 [Updated 2017 Dec 21; cited 2020 Jul 19]. Available from: https://www.paho.org/hq/dmdocuments/2017/2017-dec-21-phe-ZIKV-cases.pdf
- Abushouk AI, Negida A, Ahmed H. An updated review of Zika virus. J Clin Virol [Internet]. 2016;84:53–58.
- Ferraris P, Yssel H, Missé D. Zika virus infection: an update. Microbes Infect. 2019;21:353–360.
- França GVA, Pedi VD, Garcia MHO, et al. Congenital syndrome associated with Zika virus infection among live births in Brazil: a description of the distribution of reported and confirmed cases in 2015–2016. Epidemiol Serv Saúde. 2018;27:e2017473.
- Mottin M, Borba JVVB, Braga RC, et al. The A – Z of Zika drug discovery. Drug Discov Today. [Internet]. 2018;23:1833–1847.
- Barrows NJ, Campos RK, Powell ST, et al. Resource a screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe. 2016;259–270. DOI:10.1016/j.chom.2016.07.004
- Santos FRS, Nunes DA, Lima WG, et al. Identification of Zika virus NS2B-NS3 protease inhibitors by structure-based virtual screening and drug repurposing approaches. J Chem Inf Model. 2020;60(2):731–737.
- Devillers J. Repurposing drugs for use against Zika virus infection. SAR QSAR Environ Res. 2018;29(2):1–13.
- Han Y, Mesplède T, Xu H, et al. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities. J Med Virol. 2018;90:796–802.
- Munjal A, Khandia R, Dhama K, et al. Advances in developing therapies to combat Zika virus : current knowledge and future perspectives. Front Microbiol. 2017;8:1–19.
- Cheng F, Murray JL, Rubin DH. Drug repurposing : new treatments for Zika virus infection? Trends Mol Med. 2016;22:919–921.
- Saiz J, Martín-Acebes MA. The race to find antivirals for Zika virus. Antimicrob Agents Chemother. 2017;61:1–9.
- Xu M, Lee EM, Wen Z, et al. Identification of small molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen (2016). Nat Med. 2017;22:1101–1107.
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
- Wagner S, Wakeman S. What do patent-based measures tell us about product commercialization? Evidence from the pharmaceutical industry. Res Policy [Internet]. 2016;45:1091–1102.
- Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018;1–18. DOI:10.1038/nrd.2018.168
- Shaughnessy A. Old drugs, new tricks. Drug Dev. 2011;342:360–361.
- Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020. DOI:10.1038/d41587-020-00003-1
- Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020;44:e40.
- Trouiller P, Torreele E, Olliaro P, et al. Drugs for neglected diseases : a failure of the market and a public health failure? Trop Med Int Health. 2001;6:945–951. Available from: http://hdl.handle.net/10144/28439
- Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds : novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82:95–102.
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02662855
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02329054
- Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in guinea. PLoS Med. 13(3):e1001967. https://doi.org/10.1371/journal.pmed.1002066
- Jennifer L, McKimm-Breschkin JL. Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conferenceAntiviral Research. Antiviral Res. 2018;149:118–142.
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01227421
- Tran MN, Galt L, Bashirzadeh F. Recurrent respiratory papillomatosis: the role of cidofovir. Respirol Case Rep. 2018;6:1–3.
- Baz M, Goyette N, Griffin BD, et al. In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin. Antivir Ther. 2017;22(7):613–618.
- Bregonje M. Patents: A unique source for scientific technical information in chemistry related industry? World Patent Inf. 2005;27:309–315.
- Buchanan B. Unlocking the value of patent data: patent informatics services at the UK intellectual property office (UK-IPO). World Patent Inf. 2008;30:335–337.
- Pereira CG, Silva RR, Geciane SP. The scientific information provided through patents and its limited use in scientific research at universities. Braz J Sci Technol. 2015;2:2.
- Delwiche FA. Bibliometric analysis of scholarly publications on the Zika virus, 1952–2016. Sci Technol Libr. [Internet]. 2018;37:113–129.
- Albuquerque PC, Castro MJC, Santos-Gandelman J, et al. Bibliometric indicators of the Zika outbreak. PLoS Negl Trop Dis. 2017;11:e0005132.
- Marano G, Pupella S, Vaglio S, et al. Zika virus and the never-ending story of emerging pathogens and transfusion medicine. Blood Transfusion. 2016;14:95–100.
- Zou J, Shi PY. Strategies for Zika drug discovery. Curr Opin Virol. 2019;35:19–26.
- Hilgenfeld R. Zika virus NS1, a pathogenicity factor with many faces. EMBOM J. 2016;35(24):2631–2633.
- Zhang Z, Li Y, Loh YR, et al. Crystal structure of unlinked NS2B-NS3 protease from Zika vírus. Science. 2016;354(6319):1597–1600.
- Ramharack P, Soliman MES. Zika virus drug targets: A missing link in drug design and discovery -A route map to fill the gap. RSC Adv. 2016;6:68719–68731.
- Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513–545.
- Souza TML, Andrade NB, Bozza PT, et al. Composto antiviral, composição farmacêutica antiviral, uso do composto e método de tratamento. BR 102016012517 A2. 2016.
- Souza TML, Andrade NB, Bozza PT, et al. Composto antiviral, composição farmacêutica antiviral, uso do composto e método de Tratamento. BR 102017011488 A2. 2017.
- Junior LHGF, Freitas CBMH, Pilger DRB. Composição farmacêutica para o tratamento de infecção causada por vírus da família flaviviridae, e, uso da composição. BR 102017028623-1 A2. 2017
- Shlyakhovenko VO. Ribonucleases. Possible new approach in cancer therapy. Exp Oncol. 2016;38:2–8.
- Hodge TW. Treatment or prevention of zika virus infections by administration of a ribonuclease. WO 2017/142807 A1. 2017.
- Tang H, Lee EM, Cheng Y, et al. Compounds and methods for treatment and prevention of flavivirus infection. US 20180015153 A1. 2016.
- Chen W, Mook RA, Premont RT, et al. Niclosamide: beyond an antihelminthic drug. Cell Signal. 2018;41:89–96.
- Shibo J, Xiaohuan W, Lu ZP. Use of erythromycin in the preparation of medicines for specifically inhibiting viral infections. CN 111317739 A. 2018.
- Li H, Kramer LD, Li ZH, et al. Pharmaceutical compositions with antiflaviviral activity. WO 2017/223491 A1. 2017.
- Yakavets I, Lassalle HP, Scheglmann D, et al. Temoporfin-in-cyclodextrin-in-liposome—a new approach for anticancer drug delivery: the optimization of composition. Nanomaterials. 2018;8:1–15.
- Anderson VR, Curran M. Nitazoxanide a review of its use in the treatment of gastrointestinal infections. Drugs. 2007;67:1947–1967.
- Rana TM. Methods for treating flaviviruses and zika infections. WO 2018/136559 A1. 2018.
- Okubo K, Isono M, Asano T, et al. Lopinavir-ritonavir combination induces endoplasmic reticulum stress and kills urological cancer cells. Anticancer Res. 2019;39:5891–5901.
- Yuan S, Chan FWJ, Yuen KY, et al. Zika virus protease inhibitors and methods of use thereof. WO 2018/192083 A1. 2018.
- May JM, Owens TW, Mandler MD, et al. The antibiotic novobiocin binds and activates the ATPase that powers lipopolysaccharide transport. J Am Chem Soc. 2017;139(48):17221–17224.
- Brass AL. Inhibition of zika virus infection. 214080 A1. 2017.
- Ren P, Zou G, Bailly B, et al. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo. Emerg Microbes Infect. 2014;3(1):1–9.
- Tan WC, Sam I-C, Chong WL, et al. Polysulfonate suramin inhibits Zika virus infection. Antiviral Res. [Internet]. 2017;143:186–194.
- Shinya H, Nagayoshi K, Takashi K, et al. Pharmaceutical composition for treatment of zika virus infection. JP 2018076280A. 2018.
- Babu YS, Kotian PL, Bantia S. Methods and compositions for treatment of zika virus infection. WO 2017/155886 A1. 2017.
- Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs. 2014;74:273–282.
- Cuenca-Lopez F, Rivero A, Rivero-Juárez A. Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol. 2016. DOI:10.1080/17425255.2017.1255725.
- Du J, Nagarathnam D, Sofia MJ, et al. Nucleoside phosphoramidate prodrugs. WO 2008/121634 A2. 2008.
- Cihlar T, Clarke M, Jordan R, et al. Methods for treating zika virus infections. WO 2017/184670 A2. 2017.
- Clarke M, Jordan R, Mack-Man RL, et al. Methods for treating flaviriridae virus infections. WO2017/184668 A1. 2017.
- Li M, Yu J, Yuan J, et al. Application of Fidaxomicin in preparation of medicines treating related diseases and/or symptoms caused by Zika virus infection. CN 107737133 A. 2018.
- Cao J, Guo J, Jia X, et al. Use of digoxin in preparation of medicament for treating mammal flavivirus infection. CN 108619164 A. 2018.
- Chao MW, Chen TH, Huang HL, et al. Lanatoside C, a cardiac glycoside, acts through protein kinase C δ to cause apoptosis of human hepatocellular carcinoma cells. Nat Publ Gr [Internet]. 2017;(April):1–12. DOI:10.1038/srep46134
- Drugs.com. Lanatoside C [Internet]; [ cited 2020 Jul 20]. Available from: https://www.drugs.com/international/lanatoside-c.html
- Prendergast P. Antiviral compound and analogues thereof for treatment or prevention of flavivirus dengue/zika infections. US 2017/0348330 A1. 2017.
- Jiang S, Lu LZP. Application of Montelukast sodium in inhibiting infection of Zika virus, dengue virus and yellow fever virus. CN 106983750 A. 2017.
- Jiang S, Lu L, Zou P. Small molecular drug capable of being used for inhibiting Zika virus infection and application of drug. CN 106511346 A. 2017.
- Fanunza E, Frau A, Corona A, et al. Antiviral agents against ebola virus infection: repositioning old drugs and finding novel small molecules [Internet]. 1st ed. Annu Rep Med Chem. 2018;51:135–173. Elsevier Inc.
- Trestom AM, Warfield KL. Methods of treating zika virus infection. WO 2017/201052 Al. 2017.
- Tang H, Lee EM, Tharappel AM, et al. Emetine compounds for treatment and prevention of flavivirus infection. WO 2019/075011 A1. 2019.
- Li H, Xiong R, Xu K, et al. Novel antiviral medicines and application thereof. CN 108721281 A. 2018.
- Khalil K. Antiflaviviridae activity of anti-retroviral non-nucleoside (NNRTIS) and nucleoside reverse transcriptase inhibitors (NNRTIS). WO 2018/119371 A1. 2018.
- Chengfeng Q, Xi Z, Baoyang H, et al. Enoxacin in the prevention and/or treatment of flavivirus infection. CN 111214472 A. 2018.
- Whitby K, Pierson TC, Geiss B, et al. Castanospermine, a potent inhibitor of dengue virus infection In Vitro and In Vivo. J Virol. 2005;79:8698–8706.
- Ma J, Zhang X, Soloveva V, et al. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Antiviral Res. 2018;150:112–122.
- U.S. National Library of medicine. Clinical Trials.gov [Internet]; [ cited 2020 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT00292084?term=NCT00292084&draw=2&rank=1
- Holmes E, Ostrander G. Treatment of Zika virus infections using alpha-glucosidase inhibitors. US 20180117018 A1. 2018.
- Holmes E, Ostrander G. Treatment of Zika virus infections using alpha-glucosidase inhibitors. 20170312257 A1. 2018.
- Choi SH, Kim DM, Lim HJ, et al. Pharmaceutical composition for preventing or treating zika virus. KR 20170125484 A. 2017.
- Ke C, Liu H, Liu S, et al. Application of epigallocatechin gallate and derivatives thereof in preparing drugs for resisting against zika virus. CN 109674785 A. 2019.
- Min Z, Hongmiao L, Xingang, et al. Quercetin and its derivative are preparing the application in anti-Zika virus drug. CN109674780. 2019.
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02580279?term=NCT02580279&draw=2&rank=1
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02577393?term=NCT02577393&draw=2&rank=1
- Taliou A, Zintzaras E, Lykouras L, et al. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther. 2013;35(5):592–602.
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03943459
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04063124?term=NCT04063124&draw=2&rank=1
- Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–966.
- Chen J, Duan Y, Ji R, et al. Novel application of IFN-lambda in Zika virus infection. CN 107412739 A. 2017.
- Lai X, Lao Z, Li G, et al. Application of baicalin in preparation of medicine for preventing and treating Zika virus infection. CN 107823215 A. 2018.
- Lai X, Lao Z, Li G, et al. Application of baicalin in preparation of drug for preventing and treating Zika virus infection. CN 109453158 A. 2019.
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03830684?term=NCT03830684&draw=2&rank=1
- Rosen BD Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the ZIKA virus. US 9675582 A1. 2016.
- Feng C, He P, Tang W, et al. Application of andrographolide or derivatives thereof in preparation of Zika virus inhibitor drug. CN 108619133 A. 2018.
- Bertoglio JC, Baumgartner M, Palma R, et al. Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study. BMC Neurol. 2016;16:77.
- Michel C, Majambu M, Xiang Guo Q, et al. Methods of preventing or treating filovirus and flavivirus diseases. US 2018/0353528 A1. 2018.
- Tang H, Lee EM, Zheng W, et al. Anti-flavivirus compounds and methods of use. US 20200197369 A1. 2018.
- Vaishampayan U, Glode M, Du W, et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000;6:4205–4208.
- Kmietowicz Z. China rejects patent on hepatitis C drug sofosbuvir. BMJ. 2015;350:h3429.
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03624946
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03443830?cond=NCT03443830&draw=2&rank=1
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03425149
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02996461
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03110770
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02840487
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03008122
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02963909
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02952833
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02937233
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]. [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02996890
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03611946
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03055000
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02809443
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02887482
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03343626
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03014089
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT04064905+&cntry=&state=&city=&dist=
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03158233?term=NCT03158233&draw=2&rank=1
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04015648?term=NCT04015648&draw=2&rank=1
- U.S. National Library of medicine. ClinicalTrials.gov [Internet]; [ cited 2020 Jul 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04033068?term=NCT04033068&draw=2&rank=1